Alan S. Cleland

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 342 citations · Full text

Medicine, Nephrology, Pharmacology +13

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · Diabetes Care · 2018 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +17

Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth

Laura A. Marlow, Lisa A. Reynolds, Alan S. Cleland et al. · Cancer Research · 2009 · 68 citations · Full text

Medicine, Oncology, Pharmacology +17

Building value: Customer and shareholder

Alan S. Cleland, Albert V. Bruno · Strategy and Leadership · 1997 · 19 citations

Business, Strategic Management, Strategy +12